Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin (Januvia) for Prevention of Acute GVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
ChiCTR2500111772Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sitagliptin in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Incidence of grade II–IV acute GVHD at day +100 post-transplant. Started Nov 2025; status: recruiting.
02
Drugs
sitagliptin
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ChiCTR2500111772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111772.